Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2015 Jul 16

PMID 26177174

Citations 72

Authors

Edda Spiekerkoetter

Yon K Sung

Deepti Sudheendra

Matthew Bill

Micheala A Aldred

Marielle C van de Veerdonk

Anton Vonk Noordegraaf

Janel Long-Boyle

Rajesh Dash

Phillip C Yang

Allan Lawrie

Andrew J Swift

Marlene Rabinovitch

Roham T Zamanian

Affiliations

Soon will be listed here.

Citing Articles

Targeting Soluble TGF-β Factors: Advances in Precision Therapy for Pulmonary Arterial Hypertension.

Becher C, Wits M, de Man F, Sanchez-Duffhues G, Goumans M JACC Basic Transl Sci. 2024; 9(11):1360-1374.

PMID: 39619136 PMC: 11604486. DOI: 10.1016/j.jacbts.2024.04.005.

Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.

Corboz M, Nguyen T, Stautberg A, Cipolla D, Perkins W, Chapman R J Aerosol Med Pulm Drug Deliv. 2024; 37(5):241-283.

PMID: 39388691 PMC: 11502635. DOI: 10.1089/jamp.2024.0016.

New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review.

Rasheed A, Aslam S, Sadiq H, Ali S, Syed R, Panjiyar B Cureus. 2024; 16(8):e68117.

PMID: 39347150 PMC: 11438555. DOI: 10.7759/cureus.68117.

A guided journey through the pathophysiology of pulmonary hypertension-from measured metabolites to the mechanism of action of drugs.

Weinstein N, Carlsen J, Schulz S, Stapleton T, Henriksen H, Travnik E Front Cardiovasc Med. 2024; 11:1341145.

PMID: 38845688 PMC: 11153715. DOI: 10.3389/fcvm.2024.1341145.

The Cavin-1/Caveolin-1 interaction attenuates BMP/Smad signaling in pulmonary hypertension by interfering with BMPR2/Caveolin-1 binding.

Tomita S, Nakanishi N, Ogata T, Higuchi Y, Sakamoto A, Tsuji Y Commun Biol. 2024; 7(1):40.

PMID: 38182755 PMC: 10770141. DOI: 10.1038/s42003-023-05693-2.

References

Stacher E, Graham B, Hunt J, Gandjeva A, Groshong S, McLaughlin V . Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186(3):261-72. PMC: 3886716. DOI: 10.1164/rccm.201201-0164OC. View

Mauritz G, Kind T, Marcus J, Bogaard H, van de Veerdonk M, Postmus P . Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest. 2011; 141(4):935-943. DOI: 10.1378/chest.10-3277. View

Hoeper M, Barst R, Bourge R, Feldman J, Frost A, Galie N . Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013; 127(10):1128-38. DOI: 10.1161/CIRCULATIONAHA.112.000765. View

Spiekerkoetter E, Tian X, Cai J, Hopper R, Sudheendra D, Li C . FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013; 123(8):3600-13. PMC: 3726153. DOI: 10.1172/JCI65592. View

Thomson J, Machado R, Pauciulo M, Morgan N, Humbert M, Elliott G . Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000; 37(10):741-5. PMC: 1757155. DOI: 10.1136/jmg.37.10.741. View

Atkinson C, Stewart S, Upton P, Machado R, Thomson J, Trembath R . Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002; 105(14):1672-8. DOI: 10.1161/01.cir.0000012754.72951.3d. View

Humbert M, Sitbon O, Simonneau G . Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351(14):1425-36. DOI: 10.1056/NEJMra040291. View

Schermuly R, Dony E, Ghofrani H, Pullamsetti S, Savai R, Roth M . Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115(10):2811-21. PMC: 1236676. DOI: 10.1172/JCI24838. View

Machado R, Aldred M, James V, Harrison R, Patel B, Schwalbe E . Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006; 27(2):121-32. DOI: 10.1002/humu.20285. View

10.

Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani M, Branzi A . A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009; 30(4):394-403. PMC: 2642921. DOI: 10.1093/eurheartj/ehp022. View

11.

Kind T, Mauritz G, Marcus J, van de Veerdonk M, Westerhof N, Vonk-Noordegraaf A . Right ventricular ejection fraction is better reflected by transverse rather than longitudinal wall motion in pulmonary hypertension. J Cardiovasc Magn Reson. 2010; 12:35. PMC: 2901360. DOI: 10.1186/1532-429X-12-35. View

12.

Ghofrani H, Morrell N, Hoeper M, Olschewski H, Peacock A, Barst R . Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010; 182(9):1171-7. PMC: 3001259. DOI: 10.1164/rccm.201001-0123OC. View

13.

Benza R, Gomberg-Maitland M, Miller D, Frost A, Frantz R, Foreman A . The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2011; 141(2):354-362. DOI: 10.1378/chest.11-0676. View

14.

Deng Z, Morse J, Slager S, Cuervo N, Moore K, Venetos G . Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000; 67(3):737-44. PMC: 1287532. DOI: 10.1086/303059. View

15.

Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View